Product Images Lacosamide

This is a medication package for Lacosamide tablets containing 100 mg of the active ingredient. The recommended storage temperature is between 20°C to 25°C. The tablets are manufactured for Macleods Pharma USA, Inc. and each pack contains 60 tablets. Additionally, the package includes details for dispensing and dosage instructions.*

Each film-coated tablet contains lacosamide, USP 150 mg. The usual dosage information can be found on the package insert provided. This medication should be stored at a temperature between 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F). It is important to keep this medication out of the reach of children and dispense it in a tight container with a child-resistant closure. Manufactured by Macleods Pharmaceuticals Ltd. for Macleods Pharma USA, Inc. This product is made by Oxalis Labs in Princeton, NJ, and Baddi, Himachal Pradesh, INDIA. It comes in a pack of 60 tablets.*

This text is a label for Lacosamide tablets, USP, with a strength of 200mg. It includes information about the usual dosage, storage conditions, manufacturer details, and a reminder to dispense the Medication Guide to each patient. The tablets are distributed by Macleods Pharma USA, Inc. and manufactured in India.*

This text provides information about a medication in the form of film-coated tablets containing lacosamide, USP 50 mg. The usual dosage should be confirmed by referring to the package insert. The storage temperature recommended is between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). It advises to keep the tablets out of reach of children and for pharmacists to dispense them with a child-resistant closure. The manufacturer information includes Macleods Pharmaceuticals Ltd., with a reference to Macleods Pharma USA Inc. and Oxalis Labs, located in Princeton, NJ, and Baddi, Himachal Pradesh, INDIA.*

This text provides statistical data on the proportion of patients in a study comparing the effectiveness of a placebo versus lacosamide medication. The results show a significant difference between the two groups, with a p-value of 0.001 indicating a notable effect. The hazard ratio (HR) is reported as 0.548, which translates to a risk reduction of 45.2%. Additionally, a 95% confidence interval is provided as [0.381, 0.788]. The number at risk over time is also displayed for both treatment groups.*